Evotec Signs Two Significant Contracts with Roche
News May 01, 2006
Evotec AG has announced that it signed two significant service contracts with Roche. These contracts build on the companies’ long-standing relationship and Evotec’s positive contribution to Roche’s discovery projects.
They extend the global medicinal chemistry agreement signed in May 2004 for a further 12 months and its medicinal chemistry collaboration in oncology, signed in October 2003, for an additional 2 years.
In the global medicinal chemistry agreement a team of chemists from Evotec supports all of Roche’s European and US research sites in the design and synthesis of high quality compounds for lead finding and optimization programmes.
In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche's oncology research.
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said, "We are extremely proud to have been working with Roche since 2001 as one of their preferred partners."
"These significant research programmes announced today are of particular importance for Evotec."
"They emphasise our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE